ASSOCIATION BETWEEN INHALED CORTICOSTEROIDS AND OSTEOPOROSIS: A REVIEW

Ulfa Mustofa Nurfadilasari; Sternatami Liberitera

doi:10.62567/micjo.v2i3.1241

Authors

Ulfa Mustofa Nurfadilasari Sekolah Tinggi Ilmu Farmasi Bhakti Pertiwi
Sternatami Liberitera Universitas Sriwijaya

DOI:

https://doi.org/10.62567/micjo.v2i3.1241

Keywords:

asthma, bone mineral density, inhaled corticosteroids

Abstract

Inhaled corticosteroids (ICS) are commonly prescribed to manage asthma and chronic obstructive pulmonary disease (COPD) due to their local anti-inflammatory effects in the airways. However, prolonged or high-dose ICS use has been associated with systemic adverse effects, including decreased bone mineral density (BMD) and increased risk of osteoporosis. This review aimed to examine the association between ICS use and the risk of osteoporosis or fractures, and to identify modifying factors such as dose, duration, patient age, sex, and type of corticosteroid used. Literature review was conducted using databases including PubMed, Scopus, and Web of Science. Articles were selected using specific inclusion and exclusion criteria. The review focused on original studies published up to March 2025, resulting in 28 relevant articles, of which 6–8 high-quality studies were analyzed in depth. Most studies demonstrated that long-term or high-dose ICS use is associated with decreased BMD and increased risk of fractures, especially in elderly COPD patients. The greatest risk was linked to fluticasone and budesonide at doses ≥500 µg/day. Some studies found neutral or even protective effects in specific subgroups, indicating population-dependent variability. Meta-analyses revealed conflicting results due to heterogeneity in populations and methodologies. High-dose and long-term ICS use may increase the risk of osteoporosis. Clinicians should consider individualized risk assessments and adopt strategies such as using the lowest effective dose, monitoring BMD, and providing calcium and vitamin D supplementation in at-risk populations.

Downloads

Download data is not yet available.

References

Aljubran, S. A., Whelan, G. J., Glaum, M. C., & Lockey, R. F. (2014). Osteoporosis in the at-risk asthmatic. Allergy, 69(11), 1429–1439. https://doi.org/10.1111/all.12438

Azzahra, N. P., Yohanes, D. C., & Sumiwi, S. A. (2023). Tinjauan Pustaka : Efek Jangka Panjang Penggunaan Kortikosteroid Inhalasi Pada Pasien Asma (Indonesia). Farmaka, 21(2), 179–189.

Bhattarai, H. K., Shrestha, S., Rokka, K., & Shakya, R. (2020). Vitamin D, Calcium, Parathyroid Hormone, and Sex Steroids in Bone Health and Effects of Aging. Journal of Osteoporosis, 2020, 1–10. https://doi.org/10.1155/2020/9324505

Chalitsios, C. V, Shaw, D. E., & McKeever, T. M. (2021). Risk of Osteoporosis and Fragility Fractures in Asthma due to Oral and Inhaled Corticosteroids: Two Population-Based Nested Case-Control Studies. Thorax, 76(1), 21–28. https://doi.org/10.1136/thoraxjnl-2020-215664

Chiu, K. L., Lee, C. C., & Chen, C. Y. (2021). Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Scientific Reports, 11(1), 1–10. https://doi.org/10.1038/s41598-020-80815-y

Global Initiative for Asthma (GINA). (2025). Global Strategy for Asthma Management and Prevention. In Updated 2025.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. In A Guide for Health Care Professionals (Vol. 1).

Gonzalez, A. V., Coulombe, J., Ernst, P., & Suissa, S. (2018). Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. Chest, 153(2), 321–328. https://doi.org/10.1016/j.chest.2017.07.002

Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., … Compston, J. (2022). UK clinical guideline for the prevention and treatment of osteoporosis. In Archives of Osteoporosis (Vol. 17). https://doi.org/10.1007/s11657-022-01061-5

Grosso, A., Cazzoletti, L., Albicini, F., Gini, E., Zanolin, E., Ronzoni, V., … Cerveri, I. (2018). Use of inhaled corticosteroids and the risk of osteoporosis: an international cohort study. Epidemiology, PA4481. European Respiratory Society. https://doi.org/10.1183/13993003.congress-2018.PA4481

Grosso, A., Cerveri, I., Cazzoletti, L., Zanolin, M. E., Mattioli, V., Piloni, D., … Corsico, A. G. (2023). Inhaled corticosteroids and risk of osteoporosis in late-middle-aged subjects: a multicenter European cohort study. Minerva Medica, 114(1). https://doi.org/10.23736/S0026-4806.21.07431-0

Janson, C., Lisspers, K., Ställberg, B., Johansson, G., Gutzwiller, F. S., Mezzi, K., … Larsson, K. (2021). Osteoporosis and Fracture Risk Associated with Inhaled Corticosteroid Use Among Swedish COPD Patients: the ARCTIC Study. European Respiratory Journal, 57(2), 2000515. https://doi.org/10.1183/13993003.00515-2020

Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021). Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatology : Research and Reviews, 13, 177–190. https://doi.org/10.2147/OARRR.S282606

Liu, S. F., Kuo, H. C., Liu, G. H., Ho, S. C., Chang, H. C., Huang, H. T., … Lin, M. C. (2016). Inhaled corticosteroids can reduce osteoporosis in female patients with COPD. International Journal of COPD, 11(1), 1607–1614. https://doi.org/10.2147/COPD.S106054

Loke, Y. K., Gilbert, D., Thavarajah, M., Blanco, P., & Wilson, A. M. (2015). Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open, 5(11), e008554. https://doi.org/10.1136/bmjopen-2015-008554

Melani, A. S., Croce, S., Fabbri, G., Messina, M., & Bargagli, E. (2024). Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules, 14(2), 195. https://doi.org/10.3390/biom14020195

Ozcakir, S., Sigirli, D., Ursavas, A., & Uzaslan, E. (2020). COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids. International Journal of Chronic Obstructive Pulmonary Disease, 15, 2441–2448. https://doi.org/10.2147/COPD.S274728

Patel, R., Naqvi, S. A., Griffiths, C., & Bloom, C. I. (2020). Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review. BMJ Open Respiratory Research, 7(1), e000756. https://doi.org/10.1136/bmjresp-2020-000756

Peng, S., Tan, C., Du, L., Niu, Y., Liu, X., & Wang, R. (2023). Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulmonary Medicine, 23(1), 1–19. https://doi.org/10.1186/s12890-023-02602-5

Price, D. B., Voorham, J., Brusselle, G., Clemens, A., Kostikas, K., Stephens, J. W., … Fogel, R. (2019). Inhaled Corticosteroids in COPD and Onset of Type 2 Diabetes and Osteoporosis: Matched Cohort Study. NPJ Primary Care Respiratory Medicine, 29(1), 38. https://doi.org/10.1038/s41533-019-0150-x

Tjahjono, H. A., Haydar, F. M. S., Yuliarto, S., & Olivianto, E. (2024). Hubungan Pemakaian Steroid Inhalasi dengan Osteoporosis pada Pasien Asma Anak. Sari Pediatri, 26(3), 158–163.

Watanabe, H., Sugiyama, K., Otsuji, N., Nakano, K., Arifuku, H., Wakayama, T., … Fukushima, Y. (2023). Effect of inhaled corticosteroids on bone mineral density in patients with asthma. Asian Pacific Journal of Allergy and Immunology, 41(1), 45–52. https://doi.org/10.12932/AP-191019-0663

Zhang, N., Fan, X., Zhang, Y., Xu, N., & Li, L. (2023). Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment. Respiratory Care, 68(12), 1719–1727. https://doi.org/10.4187/respcare.10933